Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 9/20 | 0.37 |
| ▸ | PRKAA2 | P54646 | 9/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14815165 | 1.00 | PIK3CA (0.37) | PIK3CAPRKAA2JAK2JAK1HDAC1 | |
| SCHEMBL14815366 | 0.90 | DRD2 (0.40) | HCRTR2KDM4EALDH1A1 | |
| SCHEMBL14815418 | 0.90 | DRD2 (0.40) | HCRTR2KDM4EALDH1A1 | |
| SCHEMBL14815185 | 0.81 | KDM4E (0.38) | KDM4EALDH1A1 | |
| SCHEMBL14815375 | 0.81 | KDM4E (0.38) | KDM4EALDH1A1 | |
| SCHEMBL14815461 | 0.74 | LIPE (0.41) | PIK3CAPRKAA2 | |
| SCHEMBL14815383 | 0.74 | TNF (0.34) | HCRTR2 | |
| SCHEMBL14815484 | 0.74 | TNF (0.34) | HCRTR2 | |
| SCHEMBL14815276 | 0.73 | LIPE (0.38) | PIK3CAPRKAA2 | |
| SCHEMBL14814788 | 0.73 | LIPE (0.38) | PIK3CAPRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1E, CACNA1D | PIK3CA 3527/4885PRKAA2 3224/4885JAK2 1864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.